About this episode
Antimicrobial Resistance (AMR) is one of the most urgent health challenges today, making infections harder—and sometimes impossible—to treat. This episode of Fixed on ESG explores what AMR is, why it matters, and its wide-ranging impact on health systems and the global economy.
We also highlight the science behind resistance, why innovation in diagnostics, vaccines, and stewardship is critical, and what investors should consider as AMR drives rising healthcare costs, regulatory pressures, and opportunities in new technologies.
PGIM's Birgit Lundem Jakobsen, ESG Specialist, hosts this discussion with Amish Acharya, Senior Scientific and Clinical Advisor from the Fleming Initiative.
Recorded on January 20, 2026.
Get every episode summarized
Each time Fixed on ESG publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Fixed on ESG
COP30: Key Takeaways from the Amazon Summit
Fixed on ESG
Propelling Equitable Access to Medicine
Fixed on ESG
Running a Tight Ship: IMO's Net-Zero Regulations
Fixed on ESG
EU ESG Regulation: Players, Policy, and Purpose
Fixed on ESG